Company news
Plus Therapeutics, Inc. (NASDAQ:PSTV) news
Plus Therapeutics, Inc. news releases on 6ix. Latest, Oct 23, 2023: Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference…
Press releases — page 3
Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023
October 22, 2023
Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (¹⁸⁶Re) Obisbemeda in Leptomeningeal Metastases
October 9, 2023
Plus Therapeutics Enters into License Agreement for Cerebrospinal Fluid Tumor Cell Enumeration Assay
September 7, 2023
Plus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase
September 4, 2023
Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference
August 7, 2023
Plus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical Operations
July 26, 2023
Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual Meeting
June 28, 2023
Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting
June 7, 2023
Plus Therapeutics Provides Company Update Today
May 31, 2023
Plus Therapeutics Announces Topline Results from Recurrent Glioblastoma External Control Analysis at ASCO 2023
May 29, 2023
Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements
May 15, 2023
Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials
May 1, 2023
Plus Therapeutics Announces Reverse Stock Split
April 27, 2023
Plus Therapeutics Completes Phase 1/Part A of the ReSPECT-LM Clinical Trial for Leptomeningeal Metastases
April 17, 2023
Plus Therapeutics Successfully Treats First Patient in Cohort 8 of ReSPECT-GBM Phase 1/2a Trial
March 27, 2023
Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal Metastases
March 21, 2023
Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
February 22, 2023
Plus Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
February 13, 2023
Plus Therapeutics Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (¹⁸⁶Re) Obisbemeda for the Treatment of Leptomeningeal Metastases
January 31, 2023
Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma
January 17, 2023
Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
November 18, 2022
Plus Therapeutics Announces Selection of “Rhenium (186Re) Obisbemeda” as International Non-Proprietary Name for 186RNL
October 25, 2022
Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022
October 5, 2022
Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas
September 21, 2022
Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022
September 11, 2022
Plus Therapeutics Announces FDA Meeting Summary for Lead Drug Candidate
September 5, 2022
Plus Therapeutics Announces Summary of FDA Meeting on Company’s cGMP Manufacturing Process for Lead Drug Candidate
August 28, 2022
Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
July 20, 2022
Plus Therapeutics Successfully Completes Key Milestone for cGMP Manufacture of Lead Investigational Radiotherapeutic
July 11, 2022
Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial
June 21, 2022
Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial
June 15, 2022
Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
June 12, 2022
Plus Therapeutics Announces Oral Presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
April 18, 2022
Plus Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
April 7, 2022
Plus Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of 186RNL Radiotherapeutic for Leptomeningeal Metastases
March 21, 2022
Plus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
February 23, 2022
Plus Therapeutics Partners with Medidata to Apply Innovative Synthetic Control ArmⓇ Solution to Accelerate Brain Cancer Clinical Trial
February 21, 2022
Plus Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 24, 2022
February 17, 2022
Plus Therapeutics Significantly Expands Investigational Oncology Drug Pipeline
January 5, 2022
Plus Therapeutics Announces Two Significant Milestones Toward cGMP Manufacture of its Lead Investigational Radiotherapeutic
January 3, 2022
Plus Therapeutics Announces Positive Interim Data from ReSPECT™-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting
November 17, 2021
Plus Therapeutics Receives FDA Fast Track Designation for 186RNL Targeted Radiotherapeutic for Leptomeningeal Metastases
November 8, 2021
Plus Therapeutics Announces Presentation of ReSPECT-GBM Trial Dosimetery Data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting
October 26, 2021
Plus Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
October 20, 2021
Plus Therapeutics Announces FDA Clearance of Investigational New Drug Application for 186RNL for the Treatment of Leptomeningeal Metastases
October 18, 2021
Plus Therapeutics to Announce Third Quarter 2021 Financial Results and Host Conference Call on October 21, 2021
October 13, 2021
Plus Therapeutics Announces the Appointment of Industry Veteran, Norman LaFrance, M.D., as the Company’s Chief Medical Officer
September 12, 2021
Plus Therapeutics Announces Commercial Manufacturing Supply Agreement for Its Lead Investigational Drug
September 1, 2021
Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain Cancer
August 20, 2021
Plus Strengthens Commercial RNL Supply Chain with Ten Year Exclusivity Agreement
July 26, 2021